Association between increased platelet P-selectin expression and obesity in patients with type 2 diabetes: a BARI 2D (Bypass Angioplasty Revascularization Investigation 2 Diabetes) substudy

David J Schneider, Regina M Hardison, Neuza Lopes, Burton E Sobel, Maria Mori Brooks, Pro-Thrombosis Ancillary Study Group, David J Schneider, Regina M Hardison, Neuza Lopes, Burton E Sobel, Maria Mori Brooks, Pro-Thrombosis Ancillary Study Group

Abstract

Objective: To determine whether obesity increases platelet reactivity and thrombin activity in patients with type 2 diabetes plus stable coronary artery disease.

Research design and methods: We assessed platelet reactivity and markers of thrombin generation and activity in 193 patients from nine clinical sites of the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D). Blood taken at the time of enrollment was used for assay of the concentration of prothrombin fragment 1.2 (PT1.2, released when prothrombin is activated) and fibrinopeptide A (FPA, released when fibrinogen is cleaved). Platelet activation was identified with the use of flow cytometry in response to 0, 0.2, and 1 micromol/l adenosine diphosphate (ADP).

Results: Concentrations of FPA, PT1.2, and platelet activation in the absence of agonist were low. Greater BMI was associated with higher platelet reactivity in response to 1 microm ADP as assessed by surface expression of P-selectin (r = 0.29, P < 0.0001) but not reflected by the binding of fibrinogen to activated glycoprotein IIb-IIIa. BMI was not associated with concentrations of FPA or PT1.2. Platelet reactivity correlated negatively with A1C (P < 0.04), was not related to the concentration of triglycerides in blood, and did not correlate with the concentration of C-reactive peptide. CONCLUSIONS Among patients enrolled in this substudy of BARI 2D, a greater BMI was associated with higher platelet reactivity at the time of enrollment. Our results suggest that obesity and insulin resistance that accompanies obesity may influence platelet reactivity in patients with type 2 diabetes.

Figures

Figure 1
Figure 1
Distribution of platelet activation in response to ADP. The activation of platelets induced by 0.2 μmol/l ADP and 1 μmol/l ADP was quantified with the use of flow cytometry based on the surface expression of P-selectin or the binding of fluorochrome-labeled fibrinogen. Each box plot of the distribution of the percentage of platelets activated shows the median (line), the 25th and 75th percentile (box), and the 10th and 90th percentile (error bars).
Figure 2
Figure 2
Correlation between the activation of platelets identified by the surface expression of P-selectin in response to 1 μmol/l ADP and BMI in patients with diabetes. Because the activation of platelets was not normally distributed, the results were log transformed. Pearson correlation coefficient and P value are shown. The inset is a box plot showing the distribution of platelet activation in patients with a lean BMI (<25 kg/m2), overweight patients (BMI 25–30 kg/m2), obese patients (BMI 30–35 kg/m2), and morbidly obese patients (>35 kg/m2). A stepwise increment was seen with increasing BMI (P < 0.02).

References

    1. Sobel BE, Taatjes DJ, Schneider DJ: Intramural plasminogen activator inhibitor type-1 and coronary atherosclerosis. Arterioscler Thromb Vasc Biol 2003; 23: 1979– 1989
    1. Fallow GD, Singh J: The prevalence, type and severity of cardiovascular disease in diabetic and non-diabetic patients: a matched-paired retrospective analysis using coronary angiography as the diagnostic tool. Mol Cell Biochem 2004; 261: 263– 269
    1. Silva JA, Escobar A, Collins TJ, Ramee SR, White CJ: Unstable angina: a comparison of angioscopic findings between diabetic and nondiabetic patients. Circulation 1995; 92: 1731– 1736
    1. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Sabate M, Jimenez-Quevedo P, Hernandez R, Moreno R, Escaned J, Alfonso F, Banuelos C, Costa MA, Bass TA, Macaya C: Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005; 54: 2430– 2435
    1. Keating FK, Whitaker DA, Kabbani SS, Ricci MA, Sobel BE, Schneider DJ: Relation of augmented platelet reactivity to the magnitude of distribution of atherosclerosis. Am J Cardiol 2004; 94: 725– 728
    1. Librenti MC, D'Angelo A, Micossi P, Garimberti B, Mannucci PM, Pozza G: Beta-thromboglobulin and fibrinopeptide A in diabetes mellitus as markers of vascular damage. Acta Diabetol Lat 1985; 22: 39– 45
    1. Jones RL: Fibrinopeptide-A in diabetes mellitus: relation to levels of blood glucose, fibrinogen disappearance, and hemodynamic changes. Diabetes 1985; 34: 836– 843
    1. Brooks MM, Frye RL, Genuth S, Detre KM, Nesto R, Sobel BE, Kelsey SF, Orchard TJ: the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial Investigators. Hypotheses, design, and methods for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Am J Cardiol 2006; 97: 9G– 19G
    1. Basili S, Pacini G, Guagnano MT, Manigrasso MR, Santilli F, Pettinella C, Ciabattoni G, Patrono C, Davì G: Insulin resistance as a determinant of platelet activation in obese women. J Am Coll Cardiol 2006; 48: 2531– 2538
    1. Murakami T, Horigome H, Tanaka K, Nakata Y, Ohkawara K, Katayama Y, Matsui A: Impact of weight reduction on production of platelet-derived microparticles and fibrinolytic parameters in obesity. Thromb Res 2007; 119: 45– 53
    1. Rand MD, Lock JB, Veer CV, Gaffney DP, Mann KG: Blood clotting in minimally altered whole blood. Blood 1996; 88: 3432– 3445
    1. Schneider DJ, Tracy PB, Mann KG, Sobel BE: Differential effects of anticoagulants on the activation of platelets ex vivo. Circulation 1997; 96: 2877– 2883
    1. Kabbani SS, Watkins MW, Ashikaga T, Terrien EF, Holoch PA, Sobel BE, Schneider DJ: Platelet reactivity characterized prospectively: a determinant of outcome 90 days after percutaneous coronary intervention. Circulation 2001; 104: 181– 186
    1. Schneider DJ, Baumann PQ, Holmes MB, Taatjes DJ, Sobel BE: Time and dose dependent augmentation of inhibitory effects of abciximab by aspirin. Thromb Haemost 2001; 85: 309– 313
    1. Macy E, Hayes T, Tracy R: Variability in the measurement of C-reactive protein in healthy subjects: implications for reference intervals and epidemiological applications. Clin Chem 1997; 43: 52– 58
    1. Olefsky J, Reaven GM, Farquhar JW: Effects of weight reduction on obesity: studies of lipid and carbohydrate metabolism in normal and hyperlipoproteinemic subjects. J Clin Invest 1974; 53: 64– 76
    1. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB: Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999; 282: 2131– 2135
    1. Thaulow E, Erikssen J, Cohn PF: Blood platelet counts and function are related to total and cardiovascular death in apparently healthy men. Circulation 1991; 84: 613– 617
    1. Trip MD, Cats VM, van Capelle FJ, Vreeken J: Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 1990; 322: 1549– 1554
    1. Ogawa H, Nakayama M, Morimoto T, Uemura S, Kanauchi M, Doi N, Jinnouchi H, Sugiyama S, Saito Y, the Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators : Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008; 300: 2134– 2141
    1. Davì G, Guagnano MT, Ciabattoni G, Basili S, Falco A, Marinopiccoli M, Nutini M, Sensi S, Patrono C: Platelet activation in obese women: role of inflammation and oxidant stress. JAMA 2002; 288: 2008– 2014
    1. Albert MA, Danielson E, Rifai N, Ridker PM: the PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001; 286: 64– 70
    1. Keating FK, Dauerman HL, Whitaker DA, Sobel BE, Schneider DJ: Increased expression of platelet P-selectin and formation of platelet-leukocyte aggregates in blood from patients treated with unfractionated heparin plus eptifibatide compared with bivalirudin. Thromb Res 2006; 118: 361– 369
    1. Anfossi G, Russo I, Massucco P, Mattiello L, Doronzo G, De Salve A, Trovati M: Impaired synthesis and action of antiaggregating cyclic nucleotides in platelets from obese subjects: possible role in platelet hyperactivation in obesity. Eur J Clin Invest 2004; 34: 482– 489

Source: PubMed

3
Předplatit